Lakeland PeptidesPeptide therapy, explained · Lakeland & Polk County, FL

Goal

Peptides for Muscle and Performance: What Lakeland Readers Should Know

Not reviewed by a licensed provider. Read our disclaimer

Last updated

Gyms, forums and some clinics promote peptides for muscle, strength, fat loss and faster recovery. This page explains what those peptides are, what research shows, and why most are banned in tested sport. It is general information, not advice for your situation.

Overview

Most peptides sold for performance work by raising the body’s own growth hormone. The idea is that more growth hormone means more muscle and less fat. The evidence does not support that idea well.

When growth hormone itself was tested in healthy older adults, it lowered fat by about 2 kg and raised lean mass by about 2 kg, with no change in weight. It also caused more swelling, joint pain and carpal tunnel syndrome.1 A 2026 review notes that growth hormone raises lean mass largely through fluid retention, without reliably improving strength or exercise capacity in healthy adults.2

Other peptides are promoted for recovery (BPC-157, TB-500) or energy (MOTS-c, SS-31). Those claims rest mainly on animal studies.

Peptides used for muscle and performance

Growth hormone boosters

  • Sermorelin (some human trials). In a 5-month study of 19 older adults using a closely related compound, IGF-1 rose at first but fell back toward baseline, and lean mass increased in men only.3
  • Tesamorelin (FDA-approved for one use). Approved only to reduce excess belly fat in adults with HIV-related lipodystrophy, not for muscle or performance.4
  • CJC-1295 (very limited human data). Never FDA-approved.5 FDA lists serious adverse events including a fast heart rate, and says clinical data are limited.6
  • Ipamorelin (very limited human data). No human trial has measured muscle, strength or performance, and FDA found no human data for under-the-skin injections.7
  • GHRP-2 (some human trials, for diagnosis). In 126 children with growth hormone deficiency, 48 weeks of GHRP-2 raised growth hormone but did not improve growth or change IGF-1.8
  • GHRP-6 (very limited human data). Raises growth hormone, but also cortisol and appetite. No controlled trial has tested it for body composition.2

Recovery and “energy” peptides

  • BPC-157 (very limited human data). Rat studies report healing effects. No published human study used the under-the-skin, oral or nasal forms commonly sold.9
  • TB-500 (animal and lab data only). First sold as a veterinary product for racehorses. FDA found no study of it in humans.10
  • MOTS-c (animal and lab data only). Improved physical capacity in old mice. FDA found no studies giving it to people.11
  • SS-31 (elamipretide) (FDA-approved for one rare disease). In a 218-person trial in a mitochondrial muscle disease, it did not improve walking distance or fatigue.12
  • AOD-9604 (some human trials, which were negative). A growth hormone fragment developed for weight loss. Its largest trial failed.13

What to realistically expect

  • No proven gains in healthy adults. A 2026 review places the growth hormone-releasing peptides at the level of small, short hormone studies, with no controlled trials of real-world benefit and no long-term safety data.2
  • Hormone levels are not muscle. Raising growth hormone or IGF-1 has not been shown to add meaningful strength.82
  • Athletes face real penalties. WADA’s 2026 list bans, at all times, growth hormone-releasing hormone analogs (including sermorelin, tesamorelin and CJC-1295), growth hormone secretagogues (including ipamorelin), GHRP-2 and GHRP-6, AOD-9604 and TB-500.14 It also bans BPC-157 as an unapproved substance and MOTS-c as a metabolic modulator.14 Unapproved substances not named on the list are likely covered by WADA’s ban on unapproved drugs; athletes should check with their anti-doping organization.
  • 2026 compounding news is not approval. As of November 13, 2026, HHS has published a draft, non-binding policy saying it does not intend to take enforcement action against licensed pharmacies compounding certain peptides in certain forms. This is not FDA approval, and FDA has not added them to its official list.15 According to law-firm summaries, the peptides include BPC-157, TB-500 and MOTS-c.16 As of November 13, 2026, a final policy had not been published. Check the Federal Register notice for updates.15

Safety considerations

  • Growth hormone risks. For ipamorelin, FDA says known growth hormone risks, such as tumor growth, diabetes and fluid retention, cannot be ruled out.7 Tesamorelin raised IGF-1 above the normal range in many patients and raised blood sugar.4
  • Cortisol and appetite. GHRP-2 and GHRP-6 raise cortisol and appetite.2
  • Immune reactions and impurities. FDA lists these concerns for many compounded peptides.6
  • “Research” products are not made for human use. See our guide to research-chemical peptide risks.
  • Stacking several products makes it harder to know what caused a side effect.

Questions to ask a provider

  • What measurable result are you aiming for, and what evidence supports this peptide for it?
  • Is this product FDA-approved, compounded or sold for “research”? Which pharmacy makes it?
  • What lab work will you do before and during treatment?
  • Am I subject to drug testing at work or in sport, and is this substance banned?
  • How does this compare with testosterone or other options? Our peptides vs. TRT/HRT guide can help.
  • What is the total cost, and what does it include?

Footnotes

  1. Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104-115. https://doi.org/10.7326/0003-4819-146-2-200701160-00005 ↩

  2. Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Front Endocrinol (Lausanne). 2026;17:1822475. https://doi.org/10.3389/fendo.2026.1822475 ↩ ↩2 ↩3 ↩4 ↩5

  3. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. https://doi.org/10.1210/jcem.82.5.3943 ↩

  4. Theratechnologies. EGRIFTA WR (tesamorelin) for injection: prescribing information. Revised March 2025. FDA Reference ID 5557578. ↩ ↩2

  5. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting, December 4, 2024: CJC-1295-related bulk drug substances. 2024. https://www.fda.gov/media/183819/download ↩

  6. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of April 22, 2026. Accessed November 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks ↩ ↩2

  7. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee, October 29, 2024: evaluation of ipamorelin-related bulk drug substances for inclusion on the 503A Bulk Drug Substances List. 2024. https://www.fda.gov/media/182088/download ↩ ↩2

  8. Tanaka T, Hasegawa Y, Yokoya S, et al. Increased secretion of endogenous GH after treatment with an intranasal GH-releasing peptide-2 spray does not promote growth in short children with GH deficiency. Clin Pediatr Endocrinol. 2014;23(4):107-114. https://doi.org/10.1297/cpe.23.107 ↩ ↩2

  9. Tu M, Adeyemi O, Rupp T, et al. Evaluation of BPC-157-related bulk drug substances (BPC-157 free base and BPC-157 acetate) for inclusion on the 503A Bulk Drug Substances List. U.S. Food and Drug Administration; memo dated May 11, 2026. https://www.fda.gov/media/193343/download ↩

  10. Mathew B, Mattingly A, Rupp T, et al. Evaluation of TB-500-related bulk drug substances for inclusion on the 503A Bulk Drug Substances List. U.S. Food and Drug Administration. 2026. https://www.fda.gov/media/193349/download ↩

  11. Li J, Poon N-L, Asante K, et al. FDA evaluation of MOTS-c-related bulk drug substances. U.S. Food and Drug Administration; memo dated May 11, 2026. https://www.fda.gov/media/193347/download ↩

  12. Karaa A, Bertini E, Carelli V, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023;101(3):e238-e252. https://doi.org/10.1212/WNL.0000000000207402 ↩

  13. Li J, Kneeream E, Mathew B, et al. FDA evaluation of AOD-9604-related bulk drug substances. U.S. Food and Drug Administration; memo dated November 5, 2024. https://www.fda.gov/media/183584/download ↩

  14. World Anti-Doping Agency. The Prohibited List 2026. In effect January 1, 2026. https://www.wada-ama.org/en/prohibited-list ↩ ↩2

  15. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (notice of availability). Fed Regist. 2026;91(209):68526-68527. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances ↩ ↩2

  16. Sklamberg H, Kumar D, Trentacost E. HHS announces draft enforcement discretion policy paving way for pharmacies. Arnold & Porter. November 2, 2026. https://www.arnoldporter.com/en/perspectives/advisories/2026/11/hhs-announces-draft-enforcement-discretion-policy-paving-way-for-pharmacies ↩

Frequently asked questions

Do peptides build muscle?

No trial has shown that growth hormone peptides like ipamorelin, GHRP-2 or GHRP-6 build muscle or strength in healthy adults. Even growth hormone itself added lean mass mostly as fluid, without reliably improving strength. Training, protein and recovery have far stronger evidence.

Are these peptides banned in sports?

Most are. The World Anti-Doping Agency's 2026 list bans growth hormone-releasing peptides, AOD-9604, TB-500, BPC-157 and MOTS-c at all times. If you are a tested athlete, check with your anti-doping organization before using anything.

Are sermorelin and ipamorelin steroids?

No. They are peptides that signal the body to release its own growth hormone. Anti-doping rules list them separately from anabolic steroids such as testosterone, though both are banned in sport.

Questions? Talk to a licensed provider

See a free list of top rated clinics in Lakeland and Polk County, with their phone numbers and Google reviews. No one will call you.

Find a top rated provider
Find a top rated provider today